To access this material please log in or register

Register Authorize

Correction of cardiovascular risk with statins. Challenges and unsolved issues at the current stage

Arutyunov A. G., Arutyunov G. P.
State Budgetary Educational Institution of Higher Professional Education, "N. I. Pirogov Russian National Research Medical University" of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: atherosclerosis, coronary heart disease, treatment, cardiovascular risk, statins

DOI: 10.18087/rhj.2015.4.2093

The review focuses on the history of statin creation and use, which has resulted in acknowledgement of the unshakable statin position as first-line drugs for treatment of cardiovascular diseases and reducing LDL level as the major goal of the treatment.
  1. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980 Mar;35 (3):259–66.
  2. Gofman JW, Lindgren F, Elliott H, Mantz W, Hewitt J, Herring V. The role of lipids and lipoproteins in atherosclerosis. Science. 1950 Feb 17;111 (2877):166–71.
  3. Keys A. Seven countries: a multivariate analysis of death and coronary heart disease. – Harvard University Press: 1980. – 381c.
  4. Kromhout D. Serum cholesterol in cross-cultural perspective. The Seven Countries Study. Acta Cardiol. 1999 Jun;54 (3):155–8.
  5. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease – six year follow-up experience. The Framingham Study. Ann Intern Med. 1961 Jul;55:33–50.
  6. Fredrickson DS, Steinberg D. Inhibitors of cholesterol biosynthesis and the problem of hypercholesterolemia. Ann N Y Acad Sci. 1956 Nov 16;64 (4):579–89
  7. Steinberg D, Fredrickson DS, Avigan J. Effects of 4‑cholestenone in animals and in man. Proc Soc Exp Biol Med. 1958 Apr;97 (4):784–90.
  8. Blohm TR, MacKenzie RD. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch Biochem Biophys. 1959 Nov;85:245–9.
  9. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992 Nov;33 (11):1569–82.
  10. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citri­nium. J Antibiot (Tokyo). 1976 Dec;29 (12):1346–8.
  11. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982 Sep 24;248 (12):1465–77.
  12. Randomised trial of cholesterol lowering in 4444 patients with co­ronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344 (8934):1383–9.
  13. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002 Jun 29;324 (7353):1570–6.
  14. Gilyarevsky SR, Golshmid MV. Influence of race on the choice of intervention tactics for prevention of cardiovascular diseases. EJIM. 2014;01 (03):171–80.
  15. Heart Protection Study Collaborative Group. MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360 (9326):7–22.
  16. Blankstein R, Budoff MJ, Shaw LJ, Goff DC Jr, Polak JF, Lima J et al. Predictors of coronary heart disease events among asympto­matic persons with low low-density lipoprotein cholesterol MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011 Jul 19;58 (4):364–74.
  17. Juárez IE, Rivera-Silva G, Mejía-Arangure JM, Mercado-Arellano JA, Diaz-Bensussen S. Lipid profile in healthy newborn infants and its correlation with maternal lipid levels. Salud Publica Mex. 1999 Sep-Oct;41 (5):405–9.
  18. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg / dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004 Jun 2;43 (11):2142–6.
  19. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003 May 7;41 (9):1475–9.
  20. Cordain L, Eaton SB, Miller JB, Mann N, Hill K. The paradoxical nature of hunter-gatherer diets: meat based, yet non-atherogenic. Eur J Clin Nutr. 2002 Mar;56 (Suppl 1):S42–52.
  21. O'Keefe JH Jr, Cordain L. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st century hunter-gatherer. Mayo Clin Proc. 2004 Jan;79 (1):101–8.
  22. Nissen S, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 Mar 3;291 (9):1071–80.
  23. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowe­ring on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet. 2001 Feb 24;357 (9256):577–81.
  24. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002 Oct 15;106 (16):2055–60.
  25. Forrester JS. Redefining normal low-density lipoprotein choleste­rol: a strategy to unseat coronary disease as the nation's leading killer. J Am Coll Cardiol. 2010 Aug 17;56 (8):630–6.
  26. Wiviott SD, Mohanavelu S, Raichlen JS, Cain VA, Nissen SE, Libby P. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). Am J Cardiol. 2009 Jul 1;104 (1):29–35.
  27. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012 Dec 25;60 (25):2631–9.
  28. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014 Aug 5;64 (5):485–94.
  29. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376 (9753):1670–81.
  30. Brewer HB Jr. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep. 2007 Nov;9 (6):486–92.
  31. Reckless J. Addressing residual cardiovascular risk: what does the future hold? Br J Cardiol. 2012;19 (Suppl 1):s1–16.
  32. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366 (9493):1267–78.
  33. Chapman J. Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. Eur Heart J. 2005;7 (Suppl F): F56–62.
  34. Superko HR, King S 3rd. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation. 2008 Jan 29;117 (4):560–8.
  35. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998 Mar 1;81 (5):582–7.
  36. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003 Jul 15;92 (2):152–60.
  37. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol. 2002 Mar 7;89 (5A): 50C-57C.
  38. Davidson MH. Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol. 2003 Jul 16;42 (2):398–9.
  39. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010 Jan 1;105 (1):69–76.
  40. Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid le­vels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis. 2012 Sep;22 (9):697–703.
  41. Naci H, Brugts JJ, Fleurence R, Ades AE. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol. 2013 Aug;20 (4):658–70.
  42. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan;148 (1):36–69.
  43. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993 Jun 16;269 (23):3015–23.
  44. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106 (25):3143–421.
  45. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110 (2):227–39.
  46. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005 Aug 22;96 (4A): 53E-59E.
  47. Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, Hlatky MA. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med. 2006 Feb 21;144 (4):229–38.
  48. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2010 Mar 23;55 (12):1169–77.
  49. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA et al. 2010 ACCF / AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010 Dec 14;56 (25):e50–103.
  50. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC / EAS guidelines for the management of dyslipidaemias the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011 Jul;217 (1):3–46.
  51. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006 Feb 14;113 (6):791–8.
  52. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A et al. 2009 Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol. 2009 Oct;25 (10):567–79.
  53. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011 May;4 (3):337–45.
  54. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person / ten-country panel. J Intern Med. 2006 Mar;259 (3):247–58.
  55. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011 Jul 26;58 (5):457–63.
  56. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC / AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129 (25 Suppl 2):S1–45.
  57. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular diseasepPrevention in clinical practice (version 2012). The Fifth Loint Task Forse of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives os nine societies and by invited experts). Eur Heart J. 2012 Jul;33 (13):1635–701.
  58. Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R et al. Safety profile of extended-release niacin in the AIM HIGH Trial. N Engl J Med. 2014 Jul 17;371 (3):288–90.
  59. Lloyd-Jones DM. Niacin and HDL cholesterol – time to face facts. N Engl J Med. 2014 Jul 17;371 (3):271–3.
  60. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362 (17):1563–74.
  61. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G et al. Statins for primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan 31;1: CD004816.
  62. Boekholdt SM, Arsenaul BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ et al Association of LDL cholesterol, non – HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients trea­ted with statins: a meta-analysis. JAMA. 2012 Mar 28;307 (12):1302–9.
  63. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011 May;4 (3):337–45.
  64. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380 (9841):581–90.
  65. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15;365 (24):2255–67.
  66. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis. BMJ. 2003 Jun 28;326 (7404):1423.
  67. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-Full report. J Clin Lipidol. 2014 Jan-Feb;8 (1):29–60.
  68. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2015 Jan;38 (Suppl): S49–57.
  69. Rabar S, Harker M, O’Flynn N, Wierzbicki AS. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014 Jul 17;349: g4356.
  70. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: wath have we learned in the past 40 years? Pharmacotherapy. 2007 Mar;27 (3):412–24.
  71. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipideamia (the SAFARI trial). Am J Cardiol. 2005 Feb 15;95 (4):462–8.
  72. The Coronary Drug Project Research group. Clofibrate and niacin in CHD. JAMA. 1975;231 (4):360–81.
  73. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9 795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366 (9500):1849–61.
  74. Thomas T, Ginsberg H. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep. 2010 Jan;12 (1):58–65.
  75. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzoff G et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004 Feb 20;303 (5661):1201–4.
  76. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP et al. The target of ezetimibe is Niemann-Pick C1‑Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005 Jun 7;102 (23):8132–7.
  77. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005 Apr;179 (2):361–7.
  78. Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, Tunceli K. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin. 2011 Jun;27 (6):1191–210.
  79. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N Engl J Med. 2008 Apr 3;358 (14):1431–43.
  80. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al. Intensive lipid lowering with Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). N Engl J Med. 2008 Sep 25;359 (13):1343–56.
  81. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul 17;371 (3):203–12.
  82. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010 May 15;105 (10):1413–9.
  83. Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010 May;51 (5):1057–62.
  84. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowe­ring of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20;375 (9719):998–1006.
  85. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010 Apr 13;55 (15):1611–8.
  86. Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH at al Mipomersen, an apolipoprotein B synthesis inhibitor, lo­wers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012 May;33 (9):1142–9.
  87. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC / ESA Guidelines for the management of dyslipidemias: the Task Forse for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32 (14:1769–818.
  88. Jellinger PS, Smith DA, Mehta A, Ganda O, Handelsman Y, Rodbard H et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012 Mar;18 (Suppl 1):1–78.
  89. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012 Jan;35 (Suppl 1):S11–63.
  90. Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK et al. Statins decrease all-cause mortality only in CKD patients not requi­ring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res. 2013 Jun;72:35–44.
  91. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013 Jun;34 (24):1807–17.
  92. Davis KA, Miyares MA. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Am J Health Syst Pharm. 2014 Jun 15;71 (12):1001–8.
  93. Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA. 2009 Jun 16;106 (24):9546–7.
  94. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009 Apr;50 (Suppl): S172–7.
  95. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD et al. Binding of proprotein convertase subtilisin / kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007 Jun 22;282 (25):18602–12.
  96. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010 Jun 22;55 (25):2833–42.
  97. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63 (23):2541–8.
  98. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L et al. A 52‑week placebo-controlled trial of evolocumab in hyperlipi­demia. N Engl J Med. 2014 May 8;370 (19):1809–19.
  99. Gotto AM Jr, Moon JE. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study. Expert Rev Cardiovasc Ther. 2012 Aug;10 (8):955–63.
  100. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014 Jul 18;349: g4379.
Arutyunov A. G., Arutyunov G. P. Correction of cardiovascular risk with statins. Challenges and unsolved issues at the current stage. Russian Heart Journal. 2015;14 (4):193–212

To access this material please log in or register

Register Authorize
Ru En